Nosocomial outbreak of OXA-18-producing Pseudomonas aeruginosa in Tunisia  by Kalai Blagui, S. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2007.01757.x
Nosocomial outbreak of OXA-18-producing Pseudomonas aeruginosa in
Tunisia
S. Kalai Blagui1, W. Achour1, M. S. Abbassi1, M. Bejaoui1, A. Abdeladhim2 and A. Ben Hassen1
1Unite´ de Recherche, Laboratoire de Bacte´riologie Me´dicale, Centre National de Greffe de Moelle
Osseuse de Tunis and 2Institut Pasteur de Tunis, Tunis, Tunisia
ABSTRACT
Following systematic screening for ceftazidime-resistant (CAZ-R) Pseudomonas aeruginosa, 24 isolates
producing extended-spectrum b-lactamase (ESBL) were recovered during a 24-month period at the
National Bone Marrow Transplant Centre of Tunisia. These isolates were from seven immunocom-
promised patients and from environmental swabs. ESBLs inhibited by clavulanic acid were detected
by double-disk diffusion tests. Isoelectric focusing revealed that these isolates produced two to four
b-lactamases with pIs of 5.5, 6.1, 6.4, 7.6 or 8.2, and PCR detected the presence of blaOXA-18, blaSHV
and blaTEM genes in 24, 21 and two isolates, respectively. Pulsed-field gel electrophoresis defined two
dominant genotypic groups: group A (16 isolates) and group B (four isolates). Sequencing of PCR
products from representative isolates identified the blaOXA-18 gene and revealed nucleotide sequences
belonging to the blaSHV-1 and blaTEM-1 genes. Isolates producing OXA-18 belonged to genomic group
A and were isolated from four immunocompromised patients in the haematology and graft units,
and from two wash-basins in the graft unit. No immunocompromised patient harboured the clonal
epidemic strain upon admission. This is the first report of the OXA-18-type ESBL in P. aeruginosa in
Tunisia, and the first description of an outbreak caused by an OXA-18-producing strain of
P. aeruginosa.
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INTRODUCTION
Pseudomonas aeruginosa is an important nosoco-
mial pathogen that exhibits high rates of resist-
ance to antibiotics, particularly to b-lactams
[1–3]. The numerous b-lactamases can be divi-
ded into four molecular classes, designated A–D
according to their amino-acid content [4].
Extended-spectrum b-lactamases (ESBLs) that
belong to class A are inhibited by clavulanic
acid; enzymes of this class that have been
isolated previously in P. aeruginosa include
TEM-related [5–8] and SHV-related enzymes
[9–11], as well as PER-related, GES-related and
VEB-related [1] enzymes and BEL-1 [12]. ESBLs
belonging to class D are mostly point-mutant
derivatives of OXA-2 (OXA-15 and OXA-32)
[13,14] or OXA-10 (OXA-11, OXA-13, OXA-14,
OXA-16, OXA-17, OXA-19 and OXA-28) [15–20],
except for OXA-18 [2]. The activity of these
serine b-lactamases is not inhibited significantly
by clavulanic acid, except for OXA-18 [1,2,21].
The aim of the present study was to investigate
the molecular mechanisms of resistance associ-
ated with ceftazidime-resistant (CAZ-R) ESBL-
producing strains of P. aeruginosa in Tunisia.
MATERIALS AND METHODS
Bacterial strains
Twenty-four isolates were selected among 31 non-repetitive
CAZ-R P. aeruginosa isolates obtained from clinical and envi-
ronmental swabs at the National Bone Marrow Transplant
Centre (NBMTC) of Tunisia between April 1998 and June 2000.
These 24 isolates were positive in a double-disk diffusion test
and were evaluated for ESBL production. A repetitive strain
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was defined as a second isolate from the same patient and
source within a period of 1 month with the same antibiogram.
The isolates were obtained from various clinical samples from
seven neutropenic patients (21 isolates) and from environ-
mental swabs (three isolates). The seven immunocompromised
patients were receiving treatment with different b-lactam
agents, including compounds with anti-pseudomonal activity
(piperacillin–tazobactam, ceftazidime and imipenem), and
were admitted on several occasions to the graft and ⁄ or
haematology units. The isolates were identified as P. aeruginosa
by conventional microbiological methods [22].
Escherichia coli RP4 (TEM-2; pI 5.6), Klebsiella pneumoniae
D660 (TEM-1, TEM-21 and SHV-2; pIs 5.4, 6.4 and 7.6,
respectively) and K. pneumoniae CIP105166 (TEM-1, SHV-3,
SHV-1 and ACT-1; pIs 5.4, 7, 7.6 and 9, respectively) were
used as reference strains for MIC determination and in
isoelectric focusing (IEF) experiments. P. aeruginosa
ATCC 27853 was used as a reference control strain in
susceptibility tests. Positive controls for PCR included the
above strains and P. aeruginosa CIP 105 381 (OXA-18 produ-
cer). P. aeruginosa PAO1 was included in pulsed-field gel
electrophoresis (PFGE) experiments as an epidemiologically
unrelated strain, and lambda DNA concatemers (Amersham
Life Sciences, Little Chalfont, UK) were used as DNA size
markers. E. coli J53-2 was used in conjugation experiments as
a recipient strain. Plasmid DNA extracted from E. coli V517
was used as a source of reference plasmid molecules of
known molecular sizes.
Susceptibility testing
Agar disk-diffusion and MIC microdilution assays were
performed using standard procedures and were interpreted
according to the recommendations of the French Society for
Microbiology (CA-SFM) (http://www.sfm.asso.fr). Antibiotic
disks (Sanofi Diagnostic Pasteur, Marnes La Coquette,
France) used included ticarcillin, ticarcillin–clavulanic
acid, piperacillin, piperacillin–tazobactam, ceftazidime,
cefepime, aztreonam, imipenem, gentamicin, amikacin and
fosfomycin.
Double-disk diffusion tests
ESBL production by CAZ-R isolates was detected using
double-disk diffusion tests [22]. An increase in the ceftazidime,
cefepime or aztreonam zones by ticarcillin–clavulanic acid was
considered to be a positive test and was indicative of the
possible presence of an ESBL. The disks were placed 3.0 cm,
2.0 cm and 1.5 cm apart (centre-to-centre) on Mueller–Hinton
(MH) agar. To counteract the effect of high-level expression of
the intrinsic AmpC-type b-lactamase of P. aeruginosa, double-
disk synergy tests were also performed on plates containing
cloxacillin 500 mg ⁄L [23].
Analytical IEF
Crude b-lactamase extracts were prepared as described previ-
ously [2], with minor modifications. In brief, cultures were
grown overnight at 37C in 50-mL volumes of nutrient broth
containing amoxycillin 100 mg ⁄L. Cells were harvested by
centrifugation at 6000 g, washed twice, resuspended in 2 mL
of sterilised water, and sonicated for two 30-s periods with
intermediate cooling. The supernatant was collected by
centrifugation at 12 000 g for 20 min at 4C. Crude b-lactamase
extracts were subjected to analytical IEF on pH 3.5–9.5 amph-
oline polyacrylamide gels. The isoelectric points of the various
b-lactamases were identified using iodinated starch agar
containing penicillin G [24].
PFGE analysis
Nucleic acid embedded in agarose plugs was digested with
SpeI and then analysed in a CHEF DR III pulsed-field electro-
phoresis system (Bio-Rad Hercules, CA, USA) [25]. Running
conditions comprised an initial switch time of 5 s, a final
switch time of 35 s, and a run time of 24 h [26]. The resulting
DNA profiles were initially analysed visually by two different
observers. A dendrogram was then generated after compar-
ison of the molecular sizes of the DNA fragments [27] using
XLSTAT software (Addlinsoft, Paris, France) with the Dice
coefficient and UPGMA (unweighted pair-group method using
arithmetical average) clustering. A similarity cut-off level of
80% was used to group isolates in clusters of related
genotypes [28].
Screening PCR
Crude bacterial DNA extracts were prepared by heating [29]
and were used as templates in PCRs to detect b-lactamase
genes belonging to Ambler classes A and D. Three primer
pairs (Table 1) were used to detect the blaSHV, blaTEM and
blaPER-1 genes, respectively [30,31], and three additional primer
pairs detected blaOXAgroupI (OXA-5, 5 OXA-7, OXA-10 and its
Table 1. Oligonucleotides used for PCR amplification and
DNA sequencing
Primer pairs Nucleotide sequence (5¢ ﬁ 3¢) Position
PCR amplification
blaSHV GGTTATGCGTTATATTCGCC
a 1–20
TTAGCTTTGCCAGTGCTCa 865–846
blaTEM ATGAGTATTCAACATTTCCG
a 1–22
CTGACAGTTACCAATGCTTAa 861–840
blaOXA-18 ACTGGCGAATGCATCACAAC
b 10–29
ATCCTCGCAAAAACCGACAb 1185–1166
blaOXAgroup I TCAACAAATCGCCAGAGAAG
b
TCCCACACCAGAAAAACCAGb
blaOXAgroup II AAGAAACGCTACTCGCCTGC
b
CCACTCAACCCATCCTACCCb
blaPER-1 TGACGATCTGGAACCTTT
c 1053
AACTGCATAACCTACTCCc 204
DNA sequencing
blaTEM ATGAGTATTCAACATTTCCG
a 1–22
AGTACTCACCAGTCACAGAAd 305–324
TTCTGTGACTGGTGAGTACTe 324–305
GAGTAAGTAGTTCGCCAGTTe 595–576
CTGACAGTTACCAATGCTTAa 861–840
blaSHV AACTCTGCGCCGCCGCCATTA
f 350–371
GGTTATGCGTTATATTCGCCa 1–20
CGTTTCCCAGCGGTCAAGGe 489–471
TTAGCGTTGCCAGTGCTCa 865–846
blaOXA-18 CGATTACGGCAACAAGGA
b 316–335
ACTGGCGAATGCATCACAACg 10–29
TTAGGCGGGCGAAGACGAg 808–828
ATCCTCGCAAAAACCGACAb 1185–1166
aRasheed et al. [30].
bBert et al. [31].
cDe Champs et al. [23].
dGenBank no. AY392531.
eSabiha et al. [43].
fGenBank no. AF12498.
gGenBank no. U85514.
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derivatives), blaOXAgroupII (OXA-2, OXA-3, OXA-15 and OXA-
20) and blaOXA-18, respectively [31]. Reaction mixtures (50 lL)
contained 50 mM KCl, 1.5 mM MgCl2, 0.5 mM each primer,
0.4 mM each dNTP, 2.5 U Taq polymerase and 8 lL DNA. The
DNA amplification program comprised 96C for 5 min,
followed by 30 cycles of 96C for 1 min, 55C or 60C for
30 s and 72C for 1 min, followed by 5 min at 72C [30,31].
Aliquots (10 lL) of PCR products were analysed by electro-
phoresis on agarose 1.5% w ⁄v gels.
Nucleotide sequence determination
The identification of the b-lactamase gene from a representa-
tive isolate of each PFGE pattern observed was verified by
determining its sequence. A set of primers was used to amplify
two overlapping fragments covering the full-length gene
(Table 1), after which the nucleotide sequences of the PCR
products were determined by Genome Express on an ABI
Prism model 377 DNA sequencer (Perkin Elmer, Warrington,
UK). The GenBank database was then searched for homolo-
gous nucleotide sequences.
Plasmid content and transfer of resistance
Plasmid DNA was isolated from E. coli V517 [32] and donor
isolates as described by Kado and Liu [33]. Conjugation
experiments were performed by the filter mating method [34],
with E. coli J53-2 as a recipient strain [35] and individual CAZ-
R P. aeruginosa isolates as donors. Transconjugants were
selected on MH agar containing ceftazidime 10 mg ⁄L plus
rifampicin 200 mg ⁄L.
RESULTS
Bacterial isolates
ESBL-producing CAZ-R isolates of P. aeruginosa
were obtained from pus (n = 10), blood culture
(n = 4), stool (n = 3), urine (n = 2) and sputum
(n = 1) (Table 2). Isolates were also isolated from
the nose (n = 1) and from wash-basins (n = 3).
Only isolates recovered from pus, blood culture,
urine and sputum were responsible for infections,
and these were acquired in the NBMTC 7–77 days
after admission.
Susceptibility testing
ESBL-producing CAZ-R isolates represented 27%
of non-repetitive P. aeruginosa isolates. These
isolates were resistant to ceftazidime (MICs 16–
512 mg ⁄L; MIC50 64 mg ⁄L; MIC90 4096 mg ⁄L),
cefepime (MICs 32–1024 mg ⁄L; MIC50 256 mg ⁄L)
ticarcillin (MIC50 4096 mg ⁄L), ticarcillin–clavul-
anic acid (MIC50 128 mg ⁄L), piperacillin
(MIC50 256 mg ⁄L), piperacillin–tazobactam
(MIC50 128 mg ⁄L), aztreonam (MIC50 48 mg ⁄L)
and gentamicin (MIC50 512 mg ⁄L). Twenty-two
Table 2. Characteristics of ceftazidime-resistant Pseudomonas aeruginosa isolates producing extended-spectrum b-lacta-
mase
Source Unit Isolate Sample
Date
(day ⁄month ⁄ year)
MICs (mg ⁄L)
pI
Screening PCR
GroupaTIC TCC PIP TZP CAZ FEP IPM ATM blaSHV blaTEM blaOXA-18
Patient 1 HU 395 Urine 16 ⁄ 06 ⁄ 1998 4096 256 512 256 64 >512 4 64 8.2 + 7.6 + – + OG
HU 551 Pusc 18 ⁄ 07 ⁄ 1998 4096 256 512 256 64 >512 4 64 8.2 + 7.6 + – + A
HU 814a Pusc 01 ⁄ 09 ⁄ 1998 4096 128 512 256 64 256 4 48 8.2 + 7.6 + – + A
Patient 2 HU 1014 Sputum 07 ⁄ 10 ⁄ 1998 4096 128 512 256 512 256 2 256 8.2 + 7.6 + – + A
HU 1383 Stool 26 ⁄ 11 ⁄ 1998 4096 128 512 256 32 512 2 128 8.2 + 7.6 + 6.4 + 5.5 + – + A
HU 1384 Nose 26 ⁄ 11 ⁄ 1998 4096 128 256 128 32 256 2 48 8.2 + 7.6 + 6.4 + 5.5 + + + A
HU 1418b Stool 01 ⁄ 12 ⁄ 1998 4096 256 1024 512 128 >512 32 48 8.2 + 7.6 + – + A
HU 1497f Blood 14 ⁄ 12 ⁄ 1998 128 16 32 32 64 128 16 64 8.2 + 7.6 + – + A
Patient 3 PC 1295a Pusb 17 ⁄ 11 ⁄ 1998 128 128 16 16 64 32 64 48 8.2 + 5.5 – + + B
PC 1401a Pusc 30 ⁄ 11 ⁄ 1998 >256 256 128 128 32 32 64 48 8.2 + 6.4 + 6.1 – – + B
PC 1475b Pusb 10 ⁄ 12 ⁄ 1998 128 128 32 32 64 32 64 48 8.2 + 6.4 + 5.5 – – + B
PC 701a Pusb 26 ⁄ 03 ⁄ 1999 4096 256 512 256 64 256 8 48 8.2 + 7.6 + 5.5 + – + B
Patient 4 HU 1609 Pus 30 ⁄ 12 ⁄ 1998 4096 256 512 256 64 512 32 48 8.2 + 7.6 + – + OGd
Patient 5 GU 1086 Blood 05 ⁄ 05 ⁄ 1999 4096 256 512 256 64 >512 4 48 8.2 + 7.6 + – + OGd
Patient 6 GU 566 Blood 16 ⁄ 02 ⁄ 2000 4096 128 256 256 64 >512 4 48 8.2 + 7.6 + – + A
GU 633a Pus 20 ⁄ 02 ⁄ 2000 4096 128 512 128 32 512 4 48 8.2 + 7.6 + – + A
Patient 7 HU 1759 Pusb 16 ⁄ 06 ⁄ 2000 2048 64 256 128 16 256 4 48 8.2 + 7.6 + 5.5 + – + A
HU 1760 Pusc 16 ⁄ 06 ⁄ 2000 2048 128 256 128 16 256 4 64 8.2 + 7.6 + 5.5 + – + A
HU 1763 Urine 16 ⁄ 06 ⁄ 2000 2048 128 256 128 16 256 4 48 8.2 + 7.6 + 5.5 + – + A
HU 1770a Stool 17 ⁄ 06 ⁄ 2000 2048 128 256 128 16 256 2 48 8.2 + 7.6 + 5.5 + – + A
HU 1819b Blood 21 ⁄ 06 ⁄ 2000 2048 64 256 128 16 256 4 48 8.2 + 7.6 + 6.4 + 5.5 + – + A
Room 5 GU 223b Wash-basin 12 ⁄ 05 ⁄ 1999 4096 256 512 256 32 256 4 48 8.2 + 7.6 + 6.4 + – + A
Room 7 GU 244a Wash-basin 12 ⁄ 05 ⁄ 1999 4096 256 512 256 64 256 4 48 8.2 + 7.6 + 5.5 + – + OG
Nursing room GU 257 Wash-basin 18 ⁄ 05 ⁄ 1999 4096 256 1024 256 64 512 4 48 8.2 + 7.6 + 6.4 + – + A
aGenomic group A or B; OG, outgroup.
bPus, cutaneous pus.
cPus, abdomen.
dOutgroup isolates from patients 4 and 5 were identical.
HU, haematology unit; PC, paediatric consultation; GU, graft unit; TIC, ticarcillin; TCC, ticarcillin–clavulanic acid; PIP, piperacillin; TZP, tazobactam–piperacillin; CAZ,
ceftazidime; FEP, cefepime; IMP, imipenem; ATM, aztreonam.
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(92%), 20 (83%) and six (25%) of these isolates
were resistant to amikacin, fosfomycin and imi-
penem, respectively (Table 2). Most isolates had
higher cefepime MICs than ceftazidime MICs. In
most cases, synergy was demonstrated on MH
agar, but only with disks placed 2.0 cm apart.
IEF analysis
Each isolate expressed two to four b-lactamases.
All isolates appeared to produce a chromosomal
AmpC-type b-lactamase, found commonly in
P. aeruginosa, and 21 of the isolates seemed to
produce an SHV-type enzyme, as evidenced by
IEF bands in the regions typical of both enzyme
families (pI 8.2 for AmpC b-lactamases and pI 7–8.2
for SHV enzymes) (Table 2). IEF bands observed
at pIs 5.5, 6.1 or 6.4 probably represented OXA-,
CARB- or TEM-type enzymes, respectively
(http://www.lahey-org/studies/webt.htm).
PFGE analysis
PFGE analysis divided 24 ESBL-producing
CAZ-R P. aeruginosa isolates into two predom-
inant genomic groups: group A (16 isolates) and
group B (four isolates). Four other isolates
belonged to different genotypes that contained
one or two isolates each (Fig. 1). Group A isolates
were obtained from three patients in the haema-
tology unit, one patient in the graft unit, and two
wash-basins in the graft unit (Table 2).
Screening PCR
All isolates gave positive PCR results with the
primer pair detecting blaOXA-18. Twenty-one iso-
lates also yielded PCR products with the primer
pair detecting blaSHV genes. Two other isolates
were positive with the primer pair detecting blaTEM
genes. Only one isolate (no. 1384) yielded PCR
products with the primers for both blaSHV and
blaTEM genes (Table 2). None of the isolates gave
positive PCR results for blaOXAgroupI, blaOXAgroupII
or blaPER-1. Isolates producing b-lactamases with a
pI of 7.6, which aligned with the SHV-type enzyme,
were positive for blaSHV genes, and those produ-
cing b-lactamase with a pI of 5.5 were positive for
the blaOXA-18 gene. Curiously, IEF bands were not
seen at pI 5.4 for any of the blaTEM-1-positive
isolates, and bands were not observed at pI 5.5
for some blaOXA-18-positive isolates.
Gene sequencing
Analysis of the nucleotide sequences of the PCR
products from five representative isolates (1384
representing genomic group A, 1295 representing
genomic group B, and 1086, 395 and 244a repre-
senting other genomic groups) confirmed that, in
each case, the enzyme encoded was OXA-18.
Analysis of the nucleotide sequences of the PCR
products obtained from two representative iso-
lates (1384 and 1295) with the primer pair detect-
ing blaSHV genes revealed that, in both cases, the
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Fig. 1. Pulsed-field gel electrophoresis profiles of Pseudomonas aeruginosa isolates producing OXA-18. Size markers are
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enzyme encoded was SHV-1. Sequencing of the
PCR product obtained from two representative
isolates (1384 and 1295) with the primer pair
detecting blaTEM genes revealed that these isolates
harboured blaTEM-1.
Plasmid content and transfer of resistance
No plasmid was detected in the P. aeruginosa
isolates investigated in this study, and conjuga-
tion experiments failed to transfer b-lactam resist-
ance to E. coli J53-2. Therefore, the blaOXA-18 gene
seems to be chromosomally-located in these
isolates.
DISCUSSION
The most frequent mechanisms of resistance to
oxyimino-cephalosporins in P. aeruginosa involve
derepression of the AmpC chromosomal enzyme
and upregulation of multidrug efflux systems
[3,17]. In addition, many studies have investi-
gated the prevalence of ESBLs in P. aeruginosa;
according to these studies, a diverse range of
ESBLs is currently emerging in hospitals
[1,10,11,23,36–38]. All ESBLs detected in the pre-
sent study were identified as OXA-18. This
enzyme has been identified previously in only a
single P. aeruginosa isolate in France [2]. Further-
more, there are only rare reports of other
extended-spectrum oxacillinases, almost all of
which concern P. aeruginosa clinical isolates from
Turkey and France [21]. In the present study, all
P. aeruginosa isolates producing OXA-18 were
resistant to ticarcillin, ticarcillin–clavulanic acid,
piperacillin, piperacillin–tazobactam, cefepime
and aztreonam. The activity of ceftazidime was
less affected than that of cefepime, thus excluding
resistance involving over-production of cephalo-
sporinase in the CAZ-R isolates, but indicating
ESBL production [2,23,36,39].
The OXA-18-producing strain was responsible
for a small epidemic involving four immunocom-
promised patients who were hospitalised in the
haematology or graft units on several occasions
between June 1998 and June 2000. The strain was
isolated in May 1999 from two wash-basins in the
patient environment, leading to the assumption
that the hospital environment was the source of
the epidemic strain. The epidemic strain was
recovered from various clinical samples (pus,
blood and sputum) before it was recovered from
stools, which indicated that gut colonisation by
P. aeruginosa was probably not the source [40].
There was no evidence that any immunocom-
promised patient harboured P. aeruginosa strains
upon admission; thus, these strains were probably
acquired after admission. Since one patient
(patient 1) seemed to harbour two different
strains producing OXA-18, concomitant spread
of several strains producing OXA-18 could have
been occurring. The extensive use of broad-spec-
trum cephalosporins in the centre was probably
responsible for the emergence and selection of
these strains. This is the first description of
epidemic spread of P. aeruginosa strains produ-
cing OXA-18.
OXA-18 production was initially detected
among the CAZ-R isolates using a double-disk
diffusion test. The OXA-18 phenotype resembles
that of class A ESBLs, in the sense that typical
synergy is observed between ceftazidime and
clavulanate disks, which facilitates its clinical
detection [1,39]. Detection of ESBLs by double-
disk synergy tests with clavulanate and extended-
spectrum cephalosporins is a sensitive and
specific method for the detection of ESBLs in
Enterobacteriaceae. However, the same test may
not be as useful for the detection of ESBLs in
P. aeruginosa because of difficulties associated
with multiple combined mechanisms of resistance
in this species [3,23,36,39,41]. Thus, double-disk
synergy tests on MH agar containing cloxacillin
are useful for detecting ESBL production by
P. aeruginosa isolates that over-produce the
intrinsic chromosomal cephalosporinase [3,31].
In the present study, isolates producing OXA-18
displayed positive double-disk synergy tests on
both MH and MH–cloxacillin agar, suggesting the
absence of any over-expressed chromosomally-
encoded AmpC b-lactamase.
Two ESBL-producing isolates were also TEM-1
b-lactamase producers, although TEM-type
enzymes are rare in P. aeruginosa [11,31].
Twenty-two (92%) isolates were SHV-1 b-lacta-
mase producers. Such a high frequency of SHV-1
is uncommon in P. aeruginosa, and these enzymes
are currently found mainly in K. pneumoniae
[1,3,11,31,42]. PSE- and CARB-type enzymes are
the most common b-lactamases in P. aeruginosa
[31,41,43], but were not detected in the present
study, since they do not hydrolyse ceftazidime.
The failure to identify a plasmid suggested that
the gene encoding OXA-18 is chromosomally-
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mediated [2], but the isolates in the present study
were different to the isolate described by Philip-
pon et al. [2], as they were blaOXA-20-negative.
In conclusion, this study highlighted the con-
tribution of the OXA-18 ESBL to resistance to
extended-spectrum cephalosporins in P. aerugi-
nosa, and identified an OXA-18-producing strain
of P. aeruginosa for the first time in Tunisia. Early
detection of these isolates, and information con-
cerning their dissemination, are important, as
outbreaks caused by P. aeruginosa are usually
difficult to control. Finally, P. aeruginosa may, like
the Enterobacteriaceae, constitute a reservoir of
ESBL genes. The spread of P. aeruginosa strains
producing OXA-18 may be enhanced by under-
detection. The use of the double-disk synergy test,
in conjunction with cloxacillin-containing agar
plates that inhibit cephalosporinase activity, may
enhance the ability of routine diagnostic laborat-
ories to detect these organisms.
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